How much would you pay to lose 20% of your body weight? For millions of Americans, the answer might be whatever it takes. But when “whatever it takes” costs nearly $9,000 a year, the math gets complicated fast.
The new obesity wonder drugs—semaglutide and tirzepatide—are medical marvels. They work. Really work. Clinical trials show people losing 14.9% and 20.9% of their body weight respectively. That’s not a typo. We’re talking about transformative results that would make any diet guru weep with envy.
But here’s the rub: these drugs aren’t cost-effective at current prices. Not even close. Health economists, those fun-loving folks who put dollar signs on human suffering, say semaglutide needs an 81.9% price cut to make economic sense. Tirzepatide fares better, requiring only a 30.5% reduction. Only.
The numbers are sobering. Annual net prices hover around $8,412 for semaglutide and $6,236 for tirzepatide. Compare that to older medications like phentermine-topiramate, which offer better bang for the buck. Progress, apparently, comes with a premium.
Here’s where it gets interesting. These drugs prevent real problems. Tirzepatide could prevent 10,655 cardiovascular disease cases per 100,000 people treated. Semaglutide prevents 8,263. That’s impressive stuff that should theoretically save money down the road by avoiding expensive complications.
The keyword is “theoretically.” At current prices, the acquisition costs overshadow any savings from prevented heart attacks and diabetes complications. It’s like buying a $50,000 car to save $20 on gas.
Healthcare systems and employers are already feeling the squeeze. High demand has created supply shortages, and insurers are slapping on coverage restrictions faster than you can say “prior authorization.” Some employers are reconsidering their coverage strategies entirely. The analysis encompassed 126 million eligible US adults, representing the massive scale of potential impact these medications could have on the healthcare system.
The obesity epidemic affects over 40% of American adults and is projected to cost $1.2 trillion globally by 2025. Half of that spending will happen right here in the US. These drugs could be game-changers, but only if the price is right. Competition among manufacturers is expected to drive prices down, with companies like Eli Lilly and Novo Nordisk already reducing prices for direct purchases. Until then, they remain expensive solutions to an expensive problem, potentially creating a different kind of burden altogether.
